published meta-analysis   sensitivity analysis   studies

anti-inflammatoty and immuno-therapy in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsLIFESAVER, 2021 2.00 [0.16; 24.66] RECOVERY, 2022 0.87 [0.77; 0.98] 0.87[0.77; 0.98]LIFESAVER, 2021, RECOVERY, 202220%8,168moderatenot evaluable deathsdetailed resultsLIFESAVER, 2021 2.00 [0.16; 24.66] RECOVERY, 2022 0.87 [0.77; 0.98] 0.87[0.77; 0.98]LIFESAVER, 2021, RECOVERY, 202220%8,168moderatenot evaluable death or ventilationdetailed resultsRECOVERY, 2022 0.90 [0.81; 0.99] 0.90[0.81; 0.99]RECOVERY, 202210%7,905NAnot evaluable mechanical ventilationdetailed resultsRECOVERY, 2022 0.87 [0.74; 1.02] 0.87[0.74; 1.02]RECOVERY, 202210%7,905NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-02 07:06 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525 - roots T: 290